Evidence map›Paper›PMID 42399515›Full record

ArticleAnnals of surgical oncology2026

Clinical Impact and Outcomes of Neoadjuvant Systemic Therapy for Invasive Lobular Carcinoma.

Genevieve A Fasano, Jason Mouabbi, Helen M Johnson, Heather Y Lin, Kerollos Nashat Wanis, Susie X Sun, Anthony Lucci, Vicente Valero, Melissa Mitchell, Yu Shen and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Annals of surgical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Genevieve A FasanoDepartment of Breast Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Jason MouabbiDepartment of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Helen M JohnsonDepartment of Breast Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Heather Y LinDepartment of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Kerollos Nashat WanisDepartment of Breast Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Susie X SunDepartment of Breast Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Anthony LucciDepartment of Breast Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Vicente ValeroDepartment of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Melissa MitchellDepartment of Breast Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Yu ShenDepartment of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Kelly K HuntDepartment of Breast Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Henry KuererDepartment of Breast Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. hkuerer@mdanderson.org.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundStudies regarding therapeutic response of invasive lobular carcinoma (ILC) to neoadjuvant systemic therapy (NST) suggest that ILC is less favorable and the prognostic impact of a pathologic complete response (pCR) is unclear. PATIENTS AND

methodsThis study included 853 (NAC; n = 715 and NET; n = 138) non-metastatic classic ILC cases that received NST followed by surgery. Propensity-score matched analysis (PSMA) was performed to compare clinicopathologic groups. Survival outcomes were compared for patients with and without a pCR.

resultsMost had large primary tumors with nodal metastases (89.5% cT2-T4, 64% cN+) and luminal subtype tumors (87.6%). Patients receiving NAC were more likely to be clinically node-positive (69.1% versus 34.3%; p = 0.0005), have grade 3 disease (18.7% versus 8.7%; p = 0.0082), and undergo mastectomy (84.2% versus 69.6%; p < 0.001) and ALND (84.9% versus 57.3%; p < 0.0001) compared with NET. Overall, breast and axillary nodal pCR rates were 4.9% and 9.3%, respectively. Among 155 patients who had SLNB, there was 1 axillary nodal recurrence (0.6%). The 10-year distant recurrence-free survival (DRFS) for patients with a breast pCR was 61% versus 46% for those without (p = 0.267). Patients with a nodal pCR demonstrated higher 10-year DRFS (49% versus 33%; p = 0.026) and OS compared with those without (65% versus 48%; p = 0.068). No survival outcome difference was seen for patients treated with NAC versus NET on PSMA.

conclusionsNodal pCR was associated with survival outcomes in ILC and systemic therapy decision-making should be reconsidered. SLNB after NST appears to be safe and effective in ILC.

Indexed as

Antineoplastic Combined Chemotherapy ProtocolsBreast NeoplasmsCarcinoma, LobularNeoadjuvant TherapyAdultAgedChemotherapy, AdjuvantFemaleFollow-Up StudiesHumansLymphatic MetastasisMastectomyMiddle AgedNeoplasm InvasivenessNeoplasm StagingPathologic Complete ResponseInvasive lobular carcinomaNeoadjuvant chemotherapyNeoadjuvant endocrine therapyNeoadjuvant systemic therapyPathologic complete response

Identifiers

PMID42399515
PMCPMC13631023

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.